Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.
Morinaga T, Inozume T, Kawazu M, Ueda Y, Sax N, Yamashita K, Kawashima S, Nagasaki J, Ueno T, Lin J, Ohara Y, Kuwata T, Yukami H, Kawazoe A, Shitara K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Morita A, Ichihara E, Kiura K, Enokida T, Tahara M, Hasegawa Y, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Morinaga T, et al. Among authors: nakamura y. Cancer Res Commun. 2022 Jul 28;2(7):739-753. doi: 10.1158/2767-9764.CRC-22-0050. eCollection 2022 Jul. Cancer Res Commun. 2022. PMID: 36923281 Free PMC article.
Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study.
Inozume T, Namikawa K, Kato H, Yoshikawa S, Kiniwa Y, Yoshino K, Mizuhashi S, Ito T, Takenouchi T, Matsushita S, Fujisawa Y, Matsuzawa T, Sugihara S, Asai J, Kitagawa H, Maekawa T, Isei T, Yasuda M, Yamazaki N, Uhara H, Nakamura Y. Inozume T, et al. Among authors: nakamura y. J Dermatol Sci. 2023 Apr;110(1):19-26. doi: 10.1016/j.jdermsci.2023.03.008. Epub 2023 Mar 31. J Dermatol Sci. 2023. PMID: 37045720
Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study).
Namikawa K, Ito T, Yoshikawa S, Yoshino K, Kiniwa Y, Ohe S, Isei T, Takenouchi T, Kato H, Mizuhashi S, Fukushima S, Yamamoto Y, Inozume T, Fujisawa Y, Yamasaki O, Nakamura Y, Asai J, Maekawa T, Funakoshi T, Matsushita S, Nakano E, Oashi K, Kato J, Uhara H, Miyagawa T, Uchi H, Hatta N, Tsutsui K, Maeda T, Matsuya T, Yanagisawa H, Muto I, Okumura M, Ogata D, Yamazaki N. Namikawa K, et al. Among authors: nakamura y. Cancer Med. 2023 Sep;12(17):17967-17980. doi: 10.1002/cam4.6438. Epub 2023 Aug 16. Cancer Med. 2023. PMID: 37584204 Free PMC article.
Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients.
Mori T, Namikawa K, Yamazaki N, Kiniwa Y, Yamasaki O, Yoshikawa S, Inozume T, Kato H, Nakai Y, Fukushima S, Takenouchi T, Maekawa T, Matsushita S, Otsuka A, Nomura M, Baba N, Isei T, Saito S, Fujimoto N, Tanaka R, Kaneko T, Kuwatsuka Y, Matsuya T, Nagase K, Onishi M, Onuma T, Nakamura Y. Mori T, et al. Among authors: nakamura y. Front Med (Lausanne). 2023 Aug 10;10:1229937. doi: 10.3389/fmed.2023.1229937. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37636577 Free PMC article.
Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases.
Fujisawa Y, Namikawa K, Yoshino K, Kiniwa Y, Ito T, Kato H, Matsushita S, Hoashi T, Nakamura Y, Yoshikawa S, Miyagawa T, Asai J, Matsuya T, Fukushima S, Kato J, Takenouchi T, Uchi H, Masuzawa M, Yanagi T, Maekawa T. Fujisawa Y, et al. Among authors: nakamura y. Br J Dermatol. 2023 Jul 17;189(2):223-250. doi: 10.1093/bjd/ljad114. Br J Dermatol. 2023. PMID: 37017027 No abstract available.
Evaluation of prognostic prediction ability of the novel Japanese risk factor scoring system in a Japanese cohort of resectable cutaneous squamous cell carcinoma: A retrospective cross-sectional study.
Doi R, Baba N, Kato H, Nakamura M, Matsushita S, Aoki M, Fujimoto N, Kato T, Iino S, Saito S, Yasuda M, Asai J, Ishikawa M, Yatsushiro H, Kawahara Y, Inafuku K, Matsuya T, Araki R, Teramoto Y, Hasegawa M, Nakama T, Nakamura Y. Doi R, et al. Among authors: nakamura m, nakamura y. Exp Dermatol. 2023 Oct;32(10):1682-1693. doi: 10.1111/exd.14873. Epub 2023 Jul 3. Exp Dermatol. 2023. PMID: 37395158
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
Bai X, Lawless AR, Czapla JA, Gerstberger SC, Park BC, Jung S, Johnson R, Yamazaki N, Ogata D, Umeda Y, Li C, Guo J, Flaherty KT, Nakamura Y, Namikawa K, Long GV, Menzies AM, Johnson DB, Sullivan RJ, Boland GM, Si L. Bai X, et al. Among authors: nakamura y. JAAD Int. 2024 Jan 19;15:105-114. doi: 10.1016/j.jdin.2023.11.014. eCollection 2024 Jun. JAAD Int. 2024. PMID: 38500872 Free PMC article.
Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T. Sano K, et al. Among authors: nakamura y. J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(2):2309499020929786. doi: 10.1177/2309499020929786. J Orthop Surg (Hong Kong). 2020. PMID: 32539628 Free article.
14,265 results
You have reached the last available page of results. Please see the User Guide for more information.